Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 9/20 | 1.00 |
| ▸ | FYN | P06241 | 3/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 1.00 |
| ▸ | BLK | P51451 | 1/20 | 1.00 |
| ▸ | BMX | P51813 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680536 | 1.00 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL28762018 | 0.93 | EGFR (0.88) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL29717476 | 0.93 | EGFR (0.88) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL2996153 | 0.91 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL2988422 | 0.89 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL31060509 | 0.88 | FYN (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL614989 | 0.88 | FYN (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL1417861 | 0.87 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL6583797 | 0.87 | EGFR (0.81) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL2945872 | 0.87 | EGFR (0.80) | EGFRERBB2FYNSRCBLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | UNIV NEW YORK (US) | 2025-11-20 | — | — | US | claimed |
| EP-4577832-A1 | METHOD FOR PREDICTING THE RESPONSE TO AN INHIBITOR OF EGFR KINASE ACTIVITY | Indivumed GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| EP-4543931-A2 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | New York University (US) | 2025-04-30 | — | — | EP | claimed |
| CN-119866347-A | Compositions and methods comprising antibodies conjugated to covalent peptide conjugates | 纽约大学 | 2025-04-22 | — | — | CN | claimed |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-06-27 | — | — | US | claimed |
| CN-118141921-A | Use of CAMK2 inhibitors for the preparation of a medicament for reducing resistance to EGFR-driven cancers | 四川大学 | 2024-06-07 | — | — | CN | claimed |
| WO-2023250391-A9 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | NEW YORK UNIVERSITY (US) | 2024-04-25 | — | — | WO | claimed |
| EP-4335452-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-03-13 | — | — | EP | claimed |
| WO-2024043252-A1 | PHARMACEUTICAL FOR TREATING AND/OR PREVENTING CANCER | 東レ株式会社 | 2024-02-29 | — | — | WO | claimed |
| EP-4106879-A1 | IDENTIFICATION OF AN EGFR-BIN3 PATHWAY THAT ACTIVELY SUPPRESSES INVASION AND REDUCES TUMOR SIZE IN GLIOBLASTOMA | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-12-28 | — | — | EP | claimed |
| EP-4106793-A1 | EGFR INHIBITION TRIGGERS AN ADAPTIVE RESPONSE BY CO-OPTING ANTIVIRAL SIGNALING PATHWAYS IN LUNG CANCER | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-12-28 | — | — | EP | claimed |
| WO-2022197100-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | 주식회사 엘베이스 | 2022-09-22 | — | — | WO | claimed |
| CN-115068620-A | Pharmaceutical composition capable of reducing generation of arylamine impurities | 天津睿创康泰生物技术有限公司 | 2022-09-20 | — | — | CN | claimed |
| US-20220218682-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-14 | — | — | US | claimed |
| US-20220218715-A1 | NOVEL USE OF PYRROLO-PYRIDINE DERIVATIVE COMPOUND FOR PREVENTION AND/OR TREATMENT OF CANCER | VORONOI CO., LTD. (KR) | 2022-07-14 | — | — | US | claimed |
| US-20220211706-A1 | Methods and Compositions for Treating Cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-07 | — | — | US | claimed |
| US-20220110940-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS | FELICITEX THERAPEUTICS, INC. | 2022-04-14 | — | — | US | claimed |
| US-11285154-B2 | Methods and compositions for treating cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-03-29 | — | — | US | claimed |
| EP-3965896-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | The United States Government as Represented by the Department of Veterans Affairs (US) | 2022-03-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220110940-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885FYN 89/4885 |
| US-20220218715-A1 | NOVEL USE OF PYRROLO-PYRIDINE DERIVATIVE COMPOUND FOR PREVENTION AND/OR TREATMENT OF CANCER | PDPK1, MAPKAPK5, PACSIN2 | EGFR 1252/4885ERBB2 403/4885FYN 389/4885 |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | ALPG, SLC11A2, SGTA | EGFR 30/4885ERBB2 544/4885FYN 2153/4885 |
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | MICA, CD74, HLA-DRB1 | EGFR 2295/4885ERBB2 1184/4885FYN 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.